Tesarik Jan, Conde-López Cristina, Galán-Lázaro Maribel, Mendoza-Tesarik Raquel
MARGen Clinic, Granada, Spain.
Front Reprod Health. 2020 Dec 7;2:595183. doi: 10.3389/frph.2020.595183. eCollection 2020.
Luteal phase (LP) is the period of time beginning shortly after ovulation and ending either with luteolysis, shortly before menstrual bleeding, or with the establishment of pregnancy. During the LP, the corpus luteum (CL) secretes progesterone and some other hormones that are essential to prepare the uterus for implantation and further development of the embryo, the function known as uterine receptivity. LP deficiency (LPD) can occur when the secretory activity of the CL is deficient, but also in cases of normal CL function, where it is caused by a defective endometrial response to normal levels of progesterone. LPD is particularly frequent in treatments using assisted reproductive technology (ART). Controlled ovarian stimulation usually aims to obtain the highest number possible of good-quality oocytes and requires the use of gonadotropin-releasing hormone (GnRH) analogs, to prevent premature ovulation, as well as an ovulation trigger to achieve timed final oocyte maturation. Altogether, these treatments suppress pituitary secretion of luteinizing hormone (LH), required for the formation and early activity of the CL. In addition to problems of endometrial receptivity for embryos, LPD also leads to dysfunction of the local uterine immune system, with an increased risk of embryo rejection, abnormally high uterine contractility, and restriction of uterine blood flow. There are two alternatives of LPD prevention: a direct administration of exogenous progesterone to restore the physiological progesterone serum concentration independently of the CL function, on the one hand, and treatments aimed to stimulate the CL activity so as to increase endogenous progesterone production, on the other hand. In case of pregnancy, some kind of LP support is often needed until the luteal-placental shift occurs. If LPD is caused by defective response of the endometrium and uterine immune cells to normal concentrations of progesterone, a still poorly defined condition, symptomatic treatments are the only available solution currently available.
黄体期(LP)是指排卵后不久开始,在黄体溶解时结束的一段时间,黄体溶解发生在月经出血前不久,或者在怀孕确立时结束。在黄体期,黄体(CL)分泌孕酮和其他一些激素,这些激素对于使子宫为胚胎着床和进一步发育做好准备至关重要,这一功能被称为子宫容受性。黄体功能不全(LPD)可能在黄体分泌活动不足时发生,但在黄体功能正常的情况下也可能出现,此时是由子宫内膜对正常水平孕酮的反应缺陷所致。LPD在辅助生殖技术(ART)治疗中尤为常见。控制性卵巢刺激通常旨在获得尽可能多的优质卵母细胞,需要使用促性腺激素释放激素(GnRH)类似物来防止过早排卵,以及使用排卵触发剂来实现定时的最终卵母细胞成熟。总之,这些治疗会抑制垂体分泌黄体生成素(LH),而黄体生成素是黄体形成和早期活动所必需的。除了胚胎的子宫内膜容受性问题外,LPD还会导致局部子宫免疫系统功能障碍,增加胚胎排斥、子宫异常高收缩性和子宫血流受限的风险。预防LPD有两种选择:一方面直接给予外源性孕酮以独立于黄体功能恢复生理血清孕酮浓度,另一方面进行旨在刺激黄体活动以增加内源性孕酮产生的治疗。在怀孕的情况下,通常需要某种黄体支持,直到发生黄体 - 胎盘转换。如果LPD是由子宫内膜和子宫免疫细胞对正常浓度孕酮的反应缺陷引起的(这是一种仍定义不明确的情况),目前唯一可用的解决方案是对症治疗。